AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02165033 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide/Procaterol 180/10 X 4 puffs
Description: Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
Study NCT00151567 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
Study NCT03681522 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pelvic plexus block
Description: Injections of 2.5 mL of 2% lidocaine were made to the pelvic neurovascular plexus located at the end of the seminal vesicle under Doppler US guidance on each side
Study NCT03681522 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Periprostatic nerve block
Description: Injections of 2.5 mL of 2% lidocaine were made to the neurovascular bundles at the junction of the prostate-bladder-seminal vesicle on each side.
Study NCT01782170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iocide Oral Rinse
Study NCT01782170 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01579370 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quaternary ammonium
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.
Study NCT02702011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin medium dose
Study NCT01579370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital.
Study NCT01579370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quaternary ammonium and UV-C light
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
Study NCT00707473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT00707473 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Correlative studies
Study NCT00707473 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01579370 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bleach and UV-C light
Description: Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room.
Study NCT04498663 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion- and Relationship-Focused Therapeutic Interview
Description: In this study, the therapeutic interview will be one-session lasting 90 minutes. Participants will explore prior and ongoing stressful life experiences. Participants will be educated about the role of stress in pain and will be encouraged to identify links between stressors, psychological and emotional conflicts related to the stressors, and their pain symptoms. The interview will encourage the experience and expression of previously avoided emotions related to interpersonal stressors.
Study NCT01541436 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Remote Ischemic Preconditioning, Capsaicin, UV-B
Description: The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
Study NCT01541436 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Remote Ischemic Preconditioning, Capsaicin, UV-B
Description: The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
Study NCT03189589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 500 µg
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Study NCT03189589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2269557 750 µg
Description: GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
Study NCT03836378 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioXclude™
Description: The addition of BioXclude™ dehydrated human amnion-chorion membrane into deep pockets with scaling and root planing.
Study NCT04223388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum 276
Description: 5 Billion CFU/dose, serving size = 1 capsule/day
Study NCT04223388 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo product, serving size = 1 capsule/day
Study NCT01947790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone group
Study NCT01947790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin group
Study NCT02149121 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: CT-P10
Description: 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study NCT02149121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: US-licensed reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study NCT02149121 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: EU-approved reference product, 1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
Study NCT02702011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin low dose
Study NCT02702011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: empagliflozin high dose
Study NCT04810442 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nap
Description: 45-minute nap between scanning procedures
Study NCT01568320 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endovascular Treatment (Zenith)
Description: Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
Study NCT01859130 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Zimmer Persona Total Knee System
Study NCT00607152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasburicase
Description: 0.20mg/kg per day IV
Study NCT00607152 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: 100mg tablets
Study NCT03325972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
Study NCT03325972 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
Study NCT02119117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: CoQ10
Description: This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
Study NCT02119117 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
Study NCT03338985 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genetic analysis
Description: Genetic analysis of the samples taken during the surgery (hysterectomy or curettage resection) using CGH array technique.
Study NCT04185350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-NOTA-MAL-Cys39-exendin-4
Description: After 68Ga-NOTA-MAL-Cys39-exendin-4 injection, the patient drank 300-500ml of water and urinated before the PET/CT scans.
Study NCT04841993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis decoction
Description: A single 100 mL dose of cannabis decoction is administered containing 1.8 mg THC and 2.7 mg CBD.
Study NCT02702011 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04841993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis oil
Description: A single administration of 15 drops (045 mL) of cannabis oil containing 1.8 mg THC and 3.8 mg CBD.
Study NCT04841993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vaporized cannabis
Description: 100mg of vaporized cannabis is administered by Volcano vaporizer, wich containing 0.6-2 mg THC and 0.8-3 mg CBD
Study NCT02705092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subliminal priming with subliminal reward stimuli
Description: Positive words as subliminal reward (displayed for 17 ms).
Study NCT02705092 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Subliminal priming with supraliminal reward stimuli
Description: Positive words as supraliminal reward (displayed for 150 ms).
Study NCT03695887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrous Oxide Inhalant Product
Description: Nitrous Oxide Inhalant Product
Study NCT03695887 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive comparator
Study NCT01763866 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT00145626 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy and antibodies
Description: Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT01763866 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ezetimibe
Description: Administered orally once a day
Study NCT04943159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Afamelanotide
Description: Group A is administered afamelanotide implant on Days 0, 21 and 42; Group B is administered afamelanotide implant on Days 0 and 28.
Study NCT04226573 — intervention group
Intervention type: OTHER
Intervention: Preoperative anxiety levels
Description: Serums were separated from blood samples taken from all patients in the study, Using the anti-human TNF-α and IL-6 enzyme-linked immunosorbent assay (ELISA) kits in the Elisa device, the TNF-α and IL-6 cytokines will be measured to determine their concentration.~No routine blood will be drawn during the procedures. Preoperative anxiety levels will be evaluated with STAI-Continuity and STAI-Statefulness scale.
Study NCT03936673 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous nephrostomy
Study NCT02133586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ozone
Description: Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
Study NCT02133586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ozone
Description: Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
Study NCT02133586 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nitrogen dioxide
Description: Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
Study NCT02133586 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide
Description: Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
Study NCT02182791 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Study NCT02182791 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EE/NET
Study NCT03082170 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEES
Description: FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
Study NCT03082170 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: SDQ
Description: The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
Study NCT03082170 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: data review
Description: Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
Study NCT04126421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis component (acetabular cup) E1 cup
Description: Semented acetabuar cup With E1 cup
Study NCT04126421 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Prosthesis component (acetabular cup) Marathon cup
Description: Semented acetabuar cup With Marathon cup
Study NCT01467206 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Long term follow up by a coordinating physiotherapist
Description: Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
Study NCT01467206 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Description: Standard care as it is given to all stoke patients after stroke
Study NCT02091323 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: gastric bypass surgery
Description: With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
Study NCT02091323 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: gastric bypass surgery
Description: With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 \~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
Study NCT01509521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine
Description: An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
Study NCT01509521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine
Description: An infusion of maximum 4 mg/hour for maximum 60 minutes.
Study NCT03022058 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ear-EEG system
Description: Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
Study NCT05985733 — intervention group
Intervention type: OTHER
Intervention: Biochemical analysis
Description: Oxidative stress and inflammation markers were analyzed in serum and saliva of TMD and healthy subjects.
Study NCT00025363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT03054259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
Study NCT03054259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylprednisolone
Description: 100mg infusion on days 1 and 15
Study NCT03054259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 100mg infusion on days 1 and 15
Study NCT03054259 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: 250ml infusion on days 1 and 15
Study NCT03054259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Normal Saline
Description: 250ml infusion on days 1 and 15
Study NCT04416620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: The PCOS pharmaceutical care service
Description: The intervention was provided in the format of oral plus written information. The information provided included the importance of exercise and motivational messages to exercise more at home or in the gym.~The 2nd part was about the importance of decreasing the stress levels. Participants were informed to perform a simple breathing exercise on daily basis twice a day.~The 3rd part aimed at improving participants' diets. They were informed to follow specific diet recommendations and to avoid certain types of food, explaining to them how it may negatively affect their PCOS condition.~The 4th part was about the PCOS treatment that was discussed with the participants. Females were advised on the importance of using their correct treatment. They were informed of the importance of adhering to their prescribed medications, accepting that it was a long-term treatment plan, and to consult with their specialist if their treatment was not effective, or in the case of medication side effects.
Study NCT01714349 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Nerve Transfer
Description: A nerve transfer procedure will be individualized to each patient's functional deficit.
Study NCT00145626 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Miltenyi Biotec CliniMACS
Description: Stem cell selection device
Study NCT00145626 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic stem cell transplantation
Description: Allogeneic natural killer (NK)cell infusion
Study NCT03367884 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neck dissection followed by radiotherapy(50Gy) according to risk factors
Description: Neck dissection followed by radiotherapy(50Gy) according to risk factors
Study NCT03367884 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Definitive radiotherapy
Description: Definitive radiotherapy (70Gy)
Study NCT03374020 — intervention group
Intervention type: DEVICE
Intervention: Notal OCT
Description: Imaging using Notal OCT